Ribonexus is a biotech company focused on developing targeted therapies that utilize monoclonal antibodies to inhibit tumor growth in various cancer types. The company aims to improve patient outcomes by providing more effective treatment options that specifically address the mechanisms of cancer cell proliferation.
Funding
$4.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancer therapies lack specificity, leading to systemic toxicity and reduced efficacy due to off-target effects on healthy cells. Traditional treatments often fail to address the unique molecular mechanisms driving tumor growth in individual patients.
Solution
Ribonexus is developing targeted monoclonal antibody therapies designed to selectively inhibit tumor growth while minimizing harm to healthy tissues. Their approach focuses on identifying and targeting specific proteins or pathways critical for cancer cell proliferation and survival. By precisely targeting these mechanisms, Ribonexus aims to create more effective and less toxic treatment options for various cancer types. The monoclonal antibodies are engineered to bind to cancer cells, blocking their growth signals or triggering an immune response to eliminate them.
Target Audience
Ribonexus's primary target audience includes oncology researchers, clinicians, and pharmaceutical companies focused on developing and delivering innovative cancer treatments.
Features
- Monoclonal antibodies engineered for high specificity to cancer-associated antigens
- Development of therapies targeting key signaling pathways involved in tumor growth
- Antibody-drug conjugates (ADCs) that deliver cytotoxic payloads directly to cancer cells
- Preclinical validation of antibody efficacy and safety in relevant cancer models
- Companion diagnostics to identify patients most likely to respond to Ribonexus therapies